Condition or disease | Intervention/treatment | Phase |
---|---|---|
Frailty Syndrome Cognitive Impairment Sarcopenia | Other: Exercise Training Other: Exercise Training + Cognitive Training Other: Control | Not Applicable |
In the majority of the world, the population is living to a greater age. However, older age is usually associated with elevated risk of several pathologies, as well as age-related organ dysfunctions, which in turn can accelerate functional impairments, disability, or death. To identify this geriatric syndrome the term frailty phenotype has been commonly utilized. In particular, the frailty phenotype can be distinguished in physical frailty (PF) phenotype or cognitive frailty (CF) phenotype.
Despite several groups of researchers tried to develop preventive interventions to counteract the physical and cognitive frail condition of elderly, the success of this task has been tempered by the lack of standardized, and universally agreed protocols. Moreover, the limited knowledge of the neurophysiological, and biological determinants of these conditions has precluded important advances in the research of this domain.
Many factors combine to achieve a successful aging: genetics, health care and healty lifestile. Therefore, the aim of the current trial will be to understand the behaviors and the strategies that promote healthy lifestyle and successful human aging.
Oldest old participants with CF and PF will be selected from the neurorehabilitation unit of the University Hospital of Verona (Italy). Healthy oldest old and young participants will be recruited from the section of Movement Sciences of the University of Verona.
After a first phase of neurophysiological and biological examinations that will involve all the 4 groups, only CF and PF participants will be randomly assigned to an intervention program (physical exercise, physical+cognitive exercise or control). Frail participants assigned to exercise groups will then perform 1 year of intervention, 3 days per week, 1 hour per day. Afterwards, the three groups of intervention will undergo the same neurophysiological and biological examinations of the beginning of the study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Molecular and Functional Basis of Successful Aging and Frailty |
Actual Study Start Date : | September 1, 2019 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | December 31, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: CF
30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
|
Other: Exercise Training
The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
Other: Exercise Training + Cognitive Training ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum. CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts. Other: Control NO changes in lifestyle
|
Experimental: PF
30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
|
Other: Exercise Training
The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
Other: Exercise Training + Cognitive Training ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum. CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts. Other: Control NO changes in lifestyle
|
Ages Eligible for Study: | 80 Years to 90 Years (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria YH
Exclusion Criteria OH
Exclusion Criteria PF
Cut-off exclusion criteria of PF:
Exclusion Criteria CF
Cut-off exclusion criteria of CF:
Contact: Manuela Calderara | +39 0458124287 ext 00393209033512 | manuela.calderara@univr.it |
Italy | |
University of Verona | Recruiting |
Verona, Italy, 37131 | |
Contact: Manuela Calderara +390458124287 manuela.calderara@univr.it | |
Principal Investigator: Massimo Venturelli, Ph.D. | |
Principal Investigator: Maria Romanelli, Ph.D. | |
Sub-Investigator: Gaia Giuriato, MsC | |
Sub-Investigator: Stefania Fochi, Ph.D. | |
Sub-Investigator: Chiara Milanese, Ph.D. | |
Sub-Investigator: Donadelli Massimo, Ph.D. | |
Sub-Investigator: Calabria Elisa, Ph.D. | |
Sub-Investigator: Lippi Giuseppe, Ph.D. | |
Sub-Investigator: Montagnana Martina, Ph.D. | |
Sub-Investigator: Danese Elisa, Ph.D. | |
Sub-Investigator: Sbarbati Andrea, MD; Ph.D. | |
Sub-Investigator: Fabene Paolo, Ph.D. | |
Sub-Investigator: Zanolin Maria Elisabetta, Ph.D. | |
Sub-Investigator: Gomez-Lira Macarena, Ph.D. | |
Sub-Investigator: Malerba Giovanni, Ph.D. | |
Sub-Investigator: Tamburin Stefano, MD; Ph.D. | |
Sub-Investigator: Picelli Alessandro, MD; Ph.D. | |
Sub-Investigator: Fonte Cristina, Ph.D. | |
Sub-Investigator: Federico Angela, Ph.D. | |
Sub-Investigator: Pizzini Francesca, MD; Ph.D. | |
Principal Investigator: Schena Federico, MD; Ph.D. |
Principal Investigator: | Massimo Venturelli, Ph.D. | Università degli Studi di VERONA | |
Principal Investigator: | Maria Romanelli, Ph.D. | Università degli Studi di VERONA | |
Study Director: | Federico Schena, Ph.D. | Università degli Studi di VERONA | |
Study Director: | Lidia Del Piccolo, Ph.D. | Università degli Studi di VERONA |
Tracking Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | May 17, 2019 | ||||||||||||
First Posted Date ICMJE | May 24, 2019 | ||||||||||||
Last Update Posted Date | November 4, 2020 | ||||||||||||
Actual Study Start Date ICMJE | September 1, 2019 | ||||||||||||
Estimated Primary Completion Date | December 31, 2022 (Final data collection date for primary outcome measure) | ||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||
Change History | |||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||
Descriptive Information | |||||||||||||
Brief Title ICMJE | Successful Aging and Frailty | ||||||||||||
Official Title ICMJE | Molecular and Functional Basis of Successful Aging and Frailty | ||||||||||||
Brief Summary | Frailty is the term commonly utilized to describe the geriatric syndrome that exposes the elderly to increased risk of negative health-related events. The frailty phenotypes (PF: physical or CF: cognitive) have demonstrated to predict the major negative health-related outcomes in the old population and show extensive similarities with sarcopenia (for PF) or dementia (for CF). However, the role of neurophysiological and biological factors contributing to the physical and cognitive frail condition, and in particular in which way mitochondrial dysfunction, as well as the hypertrophic and atrophic pathways assessed by genes expression, metabolomics and microbiota composition are contributing to these frail conditions, are still under debate. Therefore, the aim of this trial will be to make evidence based on the behaviors and the strategies that promote healthy lifestyle and successful human aging. | ||||||||||||
Detailed Description |
In the majority of the world, the population is living to a greater age. However, older age is usually associated with elevated risk of several pathologies, as well as age-related organ dysfunctions, which in turn can accelerate functional impairments, disability, or death. To identify this geriatric syndrome the term frailty phenotype has been commonly utilized. In particular, the frailty phenotype can be distinguished in physical frailty (PF) phenotype or cognitive frailty (CF) phenotype. Despite several groups of researchers tried to develop preventive interventions to counteract the physical and cognitive frail condition of elderly, the success of this task has been tempered by the lack of standardized, and universally agreed protocols. Moreover, the limited knowledge of the neurophysiological, and biological determinants of these conditions has precluded important advances in the research of this domain. Many factors combine to achieve a successful aging: genetics, health care and healty lifestile. Therefore, the aim of the current trial will be to understand the behaviors and the strategies that promote healthy lifestyle and successful human aging. Oldest old participants with CF and PF will be selected from the neurorehabilitation unit of the University Hospital of Verona (Italy). Healthy oldest old and young participants will be recruited from the section of Movement Sciences of the University of Verona. After a first phase of neurophysiological and biological examinations that will involve all the 4 groups, only CF and PF participants will be randomly assigned to an intervention program (physical exercise, physical+cognitive exercise or control). Frail participants assigned to exercise groups will then perform 1 year of intervention, 3 days per week, 1 hour per day. Afterwards, the three groups of intervention will undergo the same neurophysiological and biological examinations of the beginning of the study. |
||||||||||||
Study Type ICMJE | Interventional | ||||||||||||
Study Phase ICMJE | Not Applicable | ||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||||||||
Condition ICMJE |
|
||||||||||||
Intervention ICMJE |
|
||||||||||||
Study Arms ICMJE |
|
||||||||||||
Publications * |
|
||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||
Recruitment Information | |||||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||||
Estimated Enrollment ICMJE |
180 | ||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||
Estimated Study Completion Date ICMJE | December 31, 2023 | ||||||||||||
Estimated Primary Completion Date | December 31, 2022 (Final data collection date for primary outcome measure) | ||||||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria YH
Exclusion Criteria OH
Exclusion Criteria PF
Exclusion Criteria CF
|
||||||||||||
Sex/Gender ICMJE |
|
||||||||||||
Ages ICMJE | 80 Years to 90 Years (Older Adult) | ||||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||||
Contacts ICMJE |
|
||||||||||||
Listed Location Countries ICMJE | Italy | ||||||||||||
Removed Location Countries | |||||||||||||
Administrative Information | |||||||||||||
NCT Number ICMJE | NCT03963050 | ||||||||||||
Other Study ID Numbers ICMJE | 27111 | ||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||||||||
Responsible Party | Massimo Venturelli, PhD, Universita di Verona | ||||||||||||
Study Sponsor ICMJE | Universita di Verona | ||||||||||||
Collaborators ICMJE | Not Provided | ||||||||||||
Investigators ICMJE |
|
||||||||||||
PRS Account | Universita di Verona | ||||||||||||
Verification Date | November 2020 | ||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |